GlassScriptPhysician profile
Stella Abayeva
NPI 1124326467
$10,408.82
in general payments reported to CMS, 2019-2025
50 companies · $2,427 in 2025
The $2,427 reported for 2025 was more than what 93% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $681 · 2022: $1,276 · 2023: $3,264 · 2024: $2,760 · 2025: $2,427.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,452.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,451.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,947.53 | 2021-2025 | Qulipta, Botox, Ubrelvy |
| Pfizer INC. | $764.89 | 2023-2025 | |
| Lundbeck LLC | $566.93 | 2023-2025 | Vyepti, Rexulti |
| Allergan, INC. | $412.22 | 2021 | |
| Harmony Biosciences LLC | $376.98 | 2022-2025 | Wakix |
| Ipsen Biopharmaceuticals, INC | $332.01 | 2023-2025 | Dysport |
| Takeda Pharmaceuticals U.S.A., INC. | $277.76 | 2023-2024 | Hyqvia, Gammagard Liquid, Trintellix |
| Merz Pharmaceuticals, LLC | $261.51 | 2022-2025 | Xeomin, Inbrija |
| Scilex Pharmaceuticals INC. | $223.29 | 2023-2024 | Ztlido |
| Ucb, INC. | $191.17 | 2022-2025 | Rystiggo, Briviact |
| Argenx US, INC. | $178.77 | 2023-2025 | Vyvgart, Vyvgart Hytrulo |
| Biohaven Pharmaceutical Holding Company LTD. | $177.32 | 2022 | |
| Sk Life Science, INC. | $173.31 | 2023-2024 | |
| Amneal Pharmaceuticals LLC | $172.02 | 2022-2025 | Rytary, Lyvispah, Crexont |
| Axsome Therapeutics, INC. | $162.60 | 2025 | Symbravo |
Show all 50 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $150.52 | 2021 | |
| Alexion Pharmaceuticals, INC. | $139.58 | 2022-2023 | Ultomiris |
| Genzyme Corporation | $139.53 | 2022-2023 | |
| Averitas Pharma INC. | $138.27 | 2023-2025 | Qutenza |
| Csl Behring | $131.74 | 2022-2025 | Hizentra |
| Amylyx Pharmaceuticals, INC. | $126.83 | 2023-2024 | Relyvrio |
| Grifols USA, LLC | $112.82 | 2022-2024 | Gamunex-C |
| Horizon Therapeutics Plc | $110.65 | 2021-2022 | |
| Lilly USA, LLC | $95.92 | 2022-2025 | Emgality, Reyvow, Zepbound |
| Medtronic, INC. | $83.23 | 2023-2025 | Percept PC Brainsense |
| Kyowa Kirin, INC. | $75.73 | 2023 | Nourianz |
| Tanabe Pharma America, INC. | $74.91 | 2022-2023 | |
| Neurocrine Biosciences, INC. | $63.44 | 2022-2025 | |
| Corium, LLC | $53.91 | 2022-2023 | Adlarity |
| Inspire Medical Systems, INC. | $53.10 | 2024 | Inspire |
| Neurelis, INC. | $52.54 | 2022-2025 | Valtoco |
| Teva Pharmaceuticals USA, INC. | $46.73 | 2025 | Austedo Xr |
| Idorsia Pharmaceuticals US INC | $45.21 | 2022-2023 | Quviviq |
| Grt US Holding, INC. | $43.33 | 2022 | |
| Currax Pharmaceuticals LLC | $43.22 | 2024-2025 | Contrave |
| Octapharma USA, INC. | $43.21 | 2024 | Panzyga |
| Biogen, INC. | $40.67 | 2023-2025 | Spinraza, Vumerity |
| Almatica Pharma LLC | $38.26 | 2022-2023 | Gralise |
| Jazz Pharmaceuticals INC. | $38.24 | 2024 | |
| Alnylam Pharmaceuticals INC. | $37.20 | 2023 | Amvuttra |
| Merck Sharp & Dohme LLC | $29.01 | 2022-2023 | Belsomra |
| Vanda Pharmaceuticals INC. | $28.66 | 2025 | Ponvory |
| Eisai INC. | $28.53 | 2025 | |
| Amgen INC. | $24.51 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $19.94 | 2024 | Nuedexta |
| Aucta Pharmaceuticals, INC. | $19.75 | 2025 | Motpoly Xr |
| Novo Nordisk INC | $16.53 | 2021 | |
| Merz North America, INC. | $15.91 | 2025 | |
| Boston Scientific Corporation | $14.54 | 2022 | |
| Forte Bio-Pharma LLC | $14.34 | 2023 | Prolate, Nalocet |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stella Abayeva listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.